Ruby Gupta
Hematology & Oncology · Dearborn, MINPI 1669707402
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,361 of the $2,628 with a category attached, or 89.8%. It is spread thinly across 32 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,534, more than ten times the $79 reported in 2019.
Across 101 payments — averaging $26.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$278
- Incyte Corporation$210
- Novartis$208
- Johnson & Johnson$203
- Gilead$154
- Lilly USA, LLC$123
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,36190%
- Education$26710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 11 | $278 |
| Incyte Corporation | 6 | $210 |
| Novartis | 10 | $208 |
| Johnson & Johnson | 8 | $203 |
| Gilead(2 entities) | 7 | $154 |
| Lilly USA, LLC | 2 | $123 |
| AstraZeneca(2 entities) | 5 | $119 |
| E.r. Squibb & Sons, L.L.C. | 2 | $116 |
| Daiichi Sankyo Inc. | 5 | $114 |
| Bristol Myers Squibb | 5 | $111 |
| Amgen | 2 | $96 |
| Jazz Pharmaceuticals Inc. | 3 | $91 |
| Pharmaessentia USA Corporation | 3 | $82 |
| Beone Medicines USA, Inc. | 3 | $82 |
| Legend Biotech USA Inc. | 3 | $75 |
| GSK | 3 | $62 |
| Beigene USA, Inc. | 2 | $58 |
| Sumitomo Pharma America, Inc. | 1 | $54 |
| Tersera Therapeutics LLC | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Eisai Inc. | 2 | $44 |
| AVEO Pharmaceuticals, Inc. | 2 | $33 |
| Blueprint Medicines Corporation | 1 | $31 |
| Sanofi | 1 | $27 |
| Pfizer | 1 | $25 |
| Genmab U.S., Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Array Biopharma Inc | 1 | $18 |
| Tolmar, Inc. | 1 | $18 |
| Pharmaand GmbH | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERZENIO$100
How this compares
$2,628 in reported general payments places this provider in the 60th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 11 | $189,092 |
| TagrissoOsimertinib Mesylate | 12 | $179,898 |
| RevlimidLenalidomide | 11 | $164,565 |
| XareltoRivaroxaban | 18 | $17,823 |
| EliquisApixaban | 22 | $12,985 |
| Anastrozole | 186 | $7,121 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $1,100 |
| Prochlorperazine Maleate | 36 | $458 |
| Dexamethasone | 31 | $436 |
| Hydroxyurea | 14 | $383 |
| Omeprazole | 43 | $303 |
| Ondansetron Hcl | 13 | $266 |
| Alendronate Sodium | 39 | $236 |
| Tamoxifen Citrate | 14 | $233 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $208 | $189,09211 claims |
| AstraZenecaTagrisso | $119 | $179,89812 claims |
| Bristol Myers SquibbRevlimid | $111 | $164,56511 claims |
| Johnson & JohnsonXarelto | $203 | $17,82318 claims |
| PfizerEliquis | $25 | $12,98522 claims |
| Lilly USA, LLCOlanzapine | $123 | $4916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Dearborn
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.